These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37088994)

  • 1. Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Nierengarten MB
    Cancer; 2023 May; 129(10):1466. PubMed ID: 37088994
    [No Abstract]   [Full Text] [Related]  

  • 2. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 6. Zanubrutinib joins the CLL treatment buffet.
    Mozas P; Delgado J
    Lancet Oncol; 2022 Aug; 23(8):965-967. PubMed ID: 35810752
    [No Abstract]   [Full Text] [Related]  

  • 7. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
    Mehraban Far P; Rullo J; Farmer J; Urton T
    Ocul Immunol Inflamm; 2022 May; 30(4):1005-1008. PubMed ID: 33539715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zanubrutinib for the treatment of chronic lymphocytic leukemia.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2023; 24(13):1409-1413. PubMed ID: 37350553
    [No Abstract]   [Full Text] [Related]  

  • 9. In brief: Zanubrutinib (Brukinsa) for CLL or SLL.
    Med Lett Drugs Ther; 2023 Feb; 65(1670):e33-e34. PubMed ID: 36877243
    [No Abstract]   [Full Text] [Related]  

  • 10. Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Woyach J; Tedeschi A; Munir T; Siddiqi T; Hillmen P; Byrd JC; Ghia P; Mulligan SP; Dai S; Amaya-Chanaga CI; Dean JP; O'Brien SM; Barr PM
    Leuk Lymphoma; 2021 Dec; 62(13):3278-3282. PubMed ID: 34384312
    [No Abstract]   [Full Text] [Related]  

  • 11. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
    Thompson PA; Ferrajoli A; O'Brien S; Wierda WG; Keating MJ; Burger JA
    Br J Haematol; 2015 Jul; 170(1):125-8. PubMed ID: 25522014
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
    Khountham S; Shindiapina P; Mo X; Lachowiez C; Wiczer T; Mousa L; Rogers KA; Andritsos LA; Woyach JA; Byrd JC; Spurgeon SE; Awan FT
    Leuk Lymphoma; 2021 Mar; 62(3):716-721. PubMed ID: 33210562
    [No Abstract]   [Full Text] [Related]  

  • 15. Zanubrutinib in B-cell malignancies.
    Das M
    Lancet Oncol; 2019 Sep; 20(9):e470. PubMed ID: 31378456
    [No Abstract]   [Full Text] [Related]  

  • 16. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
    Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS
    Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
    Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ
    Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel.
    Mauro FR; Tedeschi A; Varettoni M; Zaja F; Barosi G; Zinzani PL
    Hematol Oncol; 2024 Mar; 42(2):e3255. PubMed ID: 38362952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.